South Africa Biologics Market Size & Outlook, 2026-2033
The biologics market in South Africa is expected to reach a projected revenue of US$ 14,256.0 million by 2033. A compound annual growth rate of 9.2% is expected of South Africa biologics market from 2026 to 2033.
The South Africa biologics market generated a revenue of USD 6,991.5 million in 2025 and is expected to reach USD 14,256.0 million by 2033.
The South Africa market is expected to grow at a CAGR of 9.2% from 2026 to 2033.
In terms of segment, microbial was the largest revenue generating source in 2025.
Mammalian is the most lucrative source segment registering the fastest growth during the forecast period.
Biologics market data book summary
Market revenue in 2025
USD 6,991.5 million
Market revenue in 2033
USD 14,256.0 million
Growth rate
9.2% (CAGR from 2026 to 2033)
Largest segment
Microbial
Fastest growing segment
Mammalian
Historical data
2021 - 2024
Base year
2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Microbial, Mammalian
Key market players worldwide
Samsung BioLogics, Amgen Inc, Novo Nordisk A/S ADR, AbbVie Inc, Sanofi SA, Johnson & Johnson, Celltrion Healthcare, Bristol-Myers Squibb Co, Eli Lilly and Co, Roche Holding AG ADR
Other key industry trends
In terms of revenue, South Africa accounted for 1.1% of the global biologics market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Middle East & Africa, South Africa biologics market is projected to lead the regional market in terms of revenue in 2033.
UAE is the fastest growing regional market in Middle East & Africa and is projected to reach USD 4,995.6 million by 2033.
South Africa is expected to witness considerable growth owing to the presence of the target population in this country. Also, the business presence of international biologic manufacturers in this country is expected to boost revenue generation. However, slow economic growth as well as slow development of the healthcare system is anticipated to impede the market growth in this country in the coming years.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biologics Market Outlook will help companies and investors design strategic landscapes.
Microbial was the largest segment with a revenue share of 64.34% in 2025.
Horizon Databook has segmented the South Africa biologics market based on microbial, mammalian covering the revenue growth of each sub-segment from 2021 to 2033.
South Africa is expected to witness considerable growth owing to the presence of the target population in this country. Also, the business presence of international biologic manufacturers in this country is expected to boost revenue generation. However, slow economic growth as well as slow development of the healthcare system is anticipated to impede the market growth in this country in the coming years.
South Africa Biologics Market Source Outlook (Revenue, USD Million , 2021-2033)
Microbial
Mammalian
Others
South Africa Biologics Market Product Outlook (Revenue, USD Million , 2021-2033)
Monoclonal antibodies (MABs)
Vaccines
Recombinant Proteins
Antisense & RNAi Therapeutics
Others
South Africa Biologics Market Disease Category Outlook (Revenue, USD Million , 2021-2033)
Oncology
Infectious Diseases
Immunological Disorders
Cardiovascular Disorders
Haematological Disorders
Others
South Africa Biologics Market Manufacturing Outlook (Revenue, USD Million , 2021-2033)
In-house
Outsourced
Reasons to subscribe to Biologics Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Biologics Market Outlook databook
Our clientele includes a mix of Biologics Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa Biologics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into South Africa Biologics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.